3/5
08:00 am
vrca
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
Low
Report
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
2/23
08:13 am
vrca
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/23
08:00 am
vrca
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Low
Report
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
2/12
08:00 am
vrca
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
Medium
Report
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
2/9
08:00 am
vrca
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
Medium
Report
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
2/7
02:07 am
vrca
Verrica Pharmaceuticals (NASDAQ:VRCA) was downgraded by analysts at
Wall
Medium
Report
Verrica Pharmaceuticals (NASDAQ:VRCA) was downgraded by analysts at
Wall
1/17
01:11 am
vrca
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at
Wall S
Medium
Report
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at
Wall S
1/13
05:44 am
vrca
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/7
05:01 pm
vrca
Verrica Pharmaceuticals (NASDAQ:VRCA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Verrica Pharmaceuticals (NASDAQ:VRCA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/7
08:00 am
vrca
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Low
Report
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
12/18
08:05 am
vrca
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.
Low
Report
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.
12/18
08:03 am
vrca
Verrica Pharmaceuticals (NASDAQ:VRCA) was given a new $17.00 price target on by analysts at Loop Capital.
Low
Report
Verrica Pharmaceuticals (NASDAQ:VRCA) was given a new $17.00 price target on by analysts at Loop Capital.